Posted on 9/17/19
Linnaeus Therapeutics Closes $12 Million Series B Financing
Linnaeus Therapeutics, Inc., a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics
Posted on 9/17/19
NJ Health Insurance Fund Partners with R-Health
Bringing back the power of the close doctor-patient relationship and improving access to healthcare is the focus of a new collaborative partnership between the New Jersey . . .
Posted on 9/17/19
Does CVS Health Have Aspirations To Be a Tech Company?
CVS Health (NYSE:CVS) is best known for prescription fulfillment and consumer product sales, but the company now appears to be branching into new areas related to . . .
Posted on 9/17/19
Cigna Still Solid Despite Negative Sentiment
Summary After a solid earnings beat, Cigna still found itself returning to 52-week averages as negative sentiment puts pressure on the healthcare industry. Express Scripts effects . . .
Posted on 9/17/19
Emergency Care Partners Joins with Illinois Emergency Medicine Specialists
PENSACOLA, Fla.--(BUSINESS WIRE)--Emergency Care Partners, a leading regional provider of emergency medicine and outsourced emergency department management services to hospital facilities across Louisiana, New York, and . . .
Posted on 9/16/19
DiamiR Announces Additional $345,000 Funding from the NIH for Development of CogniMIR
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute on Aging (NIA)
Posted on 9/16/19
Firefly Health Closes $10.2 Million Series A Funding Round
Firefly Health, a technology-powered concierge medicine service for average Americans, announced today it has closed $10.2 million in a Series A funding round.
Posted on 9/16/19
Axsome Therapeutics (AXSM) Investor Presentation - Slideshow
The following slide deck was published by Axsome Therapeutics, Inc. in conjunction with this event.Download PDFREAD FULL ARTICLE HERE
Posted on 9/16/19
Pfizer Looks To Expand Market Opportunity For Its Blockbuster Drug Xtandi
SummaryThe FDA has accepted review of the sNDA for Xtandi to treat patients with metastatic hormone-sensitive prostate cancer.Xtandi was given Priority Review by the FDA for . . .
Posted on 9/16/19
Better Buy: Celgene vs. Gilead Sciences
Should you go with the biotech that's going away or the one that's bouncing back? That's pretty much the question for investors when it comes to . . .
Posted on 9/11/19
Dance Biopharm Partners With DarioHealth
Dance Biopharm Holdings, Inc., a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, announced today it has formed a strategic alliance with DarioHealth . . .
Posted on 9/11/19
Johnson & Johnson's Definitive Tests (Part 1)
SummaryA big question for every Johnson & Johnson's shareholder takes on ever more significance.Johnson & Johnson's NOTE 11 — LEGAL PROCEEDINGS to its latest 10-Q describes . . .
Posted on 9/11/19
RegenXBio (RGNX) Investor Presentation - Slideshow
The following slide deck was published by REGENXBIO Inc. in conjunction with this event.Download PDFREAD FULL ARTICLE HERE
Posted on 9/10/19
Cyware Labs Raises $3 Million in Seed Funding
Cyware Labs, a threat intelligence sharing and cyber fusion product-based security company, today announced that it has raised $3 million in seed funding
Posted on 9/10/19
Pharmco Announces Connecticut Bioprocessing Wing Expansion
Pharmco, a leading international producer of specialty alcohols and high purity solvents, announced an expansion to its packaging facility in Brookfield, Connecticut, through the creation of . . .
Posted on 9/10/19
Health Products For You Makes the Inc. 5000 List for the Second Consecutive Year
Health Products For You (HPFY), a leading health and wellness e-commerce company, marked its second appearance in a row on the Inc 5000 list. HPFY, headquartered . . .
Posted on 9/9/19
CollPlant Biotechnologies Closes on $5.5 Million Financing
CollPlant (NASDAQ:CLGN), a regenerative medicine company, announced it has closed on a total of $5.5 million in convertible loans.
Posted on 9/9/19
Better Buy: Amgen vs. Celgene
Amgen (NASDAQ:AMGN) is about to get a piece of Celgene (NASDAQ:CELG). Sort of. To ease the way for the pending acquisition of Celgene by Bristol-Myers Squibb . . .
Posted on 9/6/19
Johnson & Johnson: An Emerging Sum Of The Parts Investment Case
SummaryA sizable portion of litigation costs has been imputed in JNJ's current share price, which I believe is overblown.Improving prospects on Medical Device and Pharma segments . . .
Posted on 9/6/19
How Will Johnson & Johnson's Opioid Case Ruling Impact Big Pharma Stocks?
August 26 might be the single worst day in 2019 for the pharmaceutical industry. An Oklahoma judge found industry giant Johnson & Johnson (NYSE:JNJ) guilty of . . .
Posted on 9/4/19
Chembio Diagnostics Announces $20 Million Term Loan with Perceptive Advisors
MEDFORD, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the closing . . .
Posted on 9/4/19
Hoth Therapeutics Issues Letter to Shareholders
Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to chronic wound . . .
Posted on 9/4/19
BioMotiv and Bristol-Myers Squibb Form Strategic Partnership
CLEVELAND & NEW YORK--(BUSINESS WIRE)--BioMotiv, a mission-driven drug development accelerator that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company (NYSE: BMY) today . . .
Posted on 9/4/19
Schrödinger Announces Collaboration with AstraZeneca
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.Schrödinger’s computational platform combines physics-based modeling . . .
Posted on 9/4/19
Repare Therapeutics Raises $82.5M Series B Financing
Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, announced today the completion of a US$82.5 million

